Gilead’s shares fell 3.6% following earnings as investors reacted negatively to cautious near-term guidance implied by sequential sales declines and typical first-quarter seasonality, signaling deceleration despite solid year-over-year growth in key HIV products.

• Total product sales (ex-Veklury) reached $6.8 billion, up 8% year-over-year, but declined 12% sequentially, consistent with usual first-quarter inventory and channel mix effects.
• HIV sales grew 10% year-over-year to $5.0 billion but fell 13% sequentially due to inventory normalization and lower average realized price.
• Biktarvy HIV treatment sales increased 7% year-over-year to $3.4 billion but dropped 15% sequentially reflecting seasonal patterns.
• Oncology continued progress with Trodelvy sales up 37% year-over-year and multiple expected regulatory catalysts in H2 2026.
• Upcoming pipeline news and acquisitions signal longer-term growth, but near-term execution uncertainties weighed on sentiment.